Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart surgery drug shows promise in cutting lung complications

NCT ID NCT07237243

Disease control Sponsor: Qin Zhang Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether giving ulinastatin during heart surgery can lower the chance of lung complications like infections or breathing failure. Researchers analyzed data from over 4,500 patients and also used computer models to understand how the drug works. The results suggest ulinastatin may help, but more research is needed to be sure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ulinastatin
What this could lead to
If successful, this could point toward a way to reduce serious lung problems after heart surgery, potentially improving recovery.
What could go wrong
This is a retrospective study, not a randomized trial, so results may be influenced by other factors. The findings need confirmation in larger, more rigorous studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

4,540 people

The number who actually took part.

Started

Jan 2014

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients undergoing elective cardiac surgery, including open-heart valve repair, valve replacement with cardiopulmonary bypass, and off-pump coronary artery bypass grafting.

Ages

18 to 80 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adult patients undergoing elective cardiac surgery, including open-heart valve repair, valve replacement with cardiopulmonary bypass, and off-pump coronary artery bypass grafting, were consecutively screened for eligibility. Exclusion Criteria: (1) age \< 18 years; (2) pregnant women; (3) history of prior cardiac surgery before the current hospitalization; (4) presence of acute respiratory diseases prior to surgery, such as respiratory tract infections, respiratory failure, pleural effusion, atelectasis, pneumothorax, bronchospasm, and pneumonia; (5) administration of ulinastatin therapy prior to cardiac surgery during the current hospitalization; (6) The drug ulinastatin was utilized during the surgery, with a total intraoperative dose of less than 50,000 U; (7) history of malignancy or bone marrow transplantation. \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac disease requiring elective cardiac surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac surgery Pulmonary complication

Contacts and locations

Locations

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.